• 1
    Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology (Baltimore, Md.) 1995; 21: 7782.
  • 2
    Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (Baltimore, Md.) 1988; 8: 4936.
  • 3
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology (Baltimore, Md.) 2007; 45: 50739.
  • 4
    Owens DK. Interpretation of cost-effectiveness analyses. J. Gen. Intern. Med. 1998; 13: 71617.
  • 5
    Buti M, Casado MA, Calleja JL et al. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 2006; 23: 40919.
  • 6
    Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann. Intern. Med. 2005; 142:82131.
  • 7
    Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J. Viral Hepat. 2007; 14: 7588.
  • 8
    Sullivan SD, Veenstra DL, Chen P-J et al. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J. Gastroenterol. Hepatol. 2007; 22: 14949.
  • 9
    Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 268295.
  • 10
    Yuen MF. Revisiting the natural history of chronic hepatitis B. Impact of new concepts on clinical management. J. Gastroenterol. Hepatol. 2007; 22: 9736.
  • 11
    Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology (Baltimore, Md.) 2001; 33: 152732.
  • 12
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 12538.
  • 13
    Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 6573.
  • 14
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 67886.
  • 15
    Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 101120.
  • 16
    Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003; 348: 80816.
  • 17
    Guan R, Lai CL, Liaw YF et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B [Abstract]. J. Gastroenterol. Hepatol. 2001; 16 (Suppl. 1): A60.